KPV, also called lysine-proline-valine or alpha-MSH 11-13, is a three-amino-acid peptide fragment studied mainly for anti-inflammatory signaling. The available KPV-specific therapeutic data are limited, and some indexed human trial records are indirect. Chia does not currently offer KPV; this page is for education only.
Wondering if peptide therapy is right for you? Take the 3-min clinical quiz.
See if you qualify →What it is
KPV is short for lysine-proline-valine. In the supplied research, it is described as alpha-MSH 11-13, meaning amino acids 11 through 13 of alpha-melanocyte-stimulating hormone, also called alpha-MSH 8.
Names: KPV, lysine-proline-valine, and alpha-MSH 11-13
KPV is a 3-amino-acid tripeptide. The names KPV, lysine-proline-valine, and alpha-MSH 11-13 point to the same short peptide sequence in the cited animal fever study 8.
How KPV relates to alpha-melanocyte-stimulating hormone
Alpha-melanocyte-stimulating hormone is a larger signaling peptide. KPV is a small C-terminal fragment of that hormone in the supplied literature, so researchers study it as part of melanocortin-related signaling rather than as a full hormone replacement 8, 12.
What KPV is being studied for, without overstating benefits
KPV is often discussed in the same conversation as anti-inflammatory peptides, gut inflammation research, and skin-barrier biology. The careful wording is important: the supplied evidence supports discussion of animal fever effects and cell signaling, not a claim that KPV improves inflammatory disease in people 8, 12.
| Term | Plain meaning | What the supplied evidence supports |
|---|---|---|
| KPV | Lysine-proline-valine | A short peptide sequence named in animal fever research 8 |
| Alpha-MSH 11-13 | A fragment of alpha-melanocyte-stimulating hormone | A way researchers describe KPV in peptide-signaling studies 8, 12 |
| Tripeptide | A peptide made of 3 amino acids | A structural description, not proof of benefit 8 |
| Anti-inflammatory signaling | Cell pathways linked to inflammation control | Studied in animal and cell models; patient outcomes are not established from the supplied KPV-specific evidence 8, 12 |
Mechanism of action
The proposed mechanism for KPV involves melanocortin-related signaling and inflammation pathways. In humans, the clinical mechanism is not established by the supplied evidence; the strongest KPV-specific data here are animal fever work and human skin-cell signaling work 8, 12.
Melanocortin-related signaling and inflammation pathways
In a rabbit study, alpha-MSH 11-13, named as lysine-proline-valine, was studied for its effect on fever 8. That supports a discussion of animal fever biology, but it does not prove KPV helps fever, gut inflammation, skin healing, or pain in people.
What cell research in human keratinocytes can and cannot show
Human keratinocyte cells are skin cells grown and studied in a lab. Elliott and colleagues studied alpha-MSH, MSH 11-13 KPV, and ACTH signaling in human keratinocyte cells, which supports a discussion of cellular signaling in skin biology 12.
Cell research is useful because it can show what a compound may do in a controlled lab setting. It cannot show whether a peptide improves symptoms, heals skin, changes disease activity, or is safe when used by a patient.
Why preclinical anti-inflammatory findings do not prove patient outcomes
Animal and cell studies help researchers ask better questions. They do not replace human trials that measure clinical outcomes, side effects, drug interactions, and longer-term safety. That is why our KPV peptide guide separates mechanism ideas from proven patient results.
Evidence
The assigned evidence grade for KPV is A, but this needs careful interpretation. The grade describes the quantity and design of indexed evidence, not whether the substance works, and not whether it is safe.
How to interpret the assigned evidence grade
The retrieved record set includes human randomized trials, including studies of hydrocortisone in newborn lung disease, erythropoietin in newborn brain injury, imaging assessment in colorectal liver metastases, fertility medication in IVF, and videolaryngoscopy predictors 1, 2, 3, 5, 7. These records help explain the database grade, but their titles do not make them KPV therapeutic trials.
This is a good example of why PubMed counts need human review. A high grade based on indexed record design does not mean KPV has shown clinical benefit for inflammation, gut disease, skin healing, or any other patient outcome.
KPV-specific preclinical findings
The clearest KPV-specific animal record in the supplied set is Richards and Lipton's rabbit fever study of alpha-MSH 11-13, also named lysine-proline-valine 8. Because this was animal research, it should be read as biology research, not as evidence that KPV changes fever or inflammation outcomes in people.
The clearest KPV-specific cell record is the human keratinocyte signaling study by Elliott and colleagues 12. That work supports discussion of skin-cell signaling, but it does not establish skin-barrier, wound-healing, or dermatology benefits in patients.
Human evidence limitations and why indirect trial records should not be treated as proof of benefit
Several retrieved human clinical records are about other interventions or disease areas, such as irreversible electroporation for liver or pancreatic cancer and consensus management recommendations for adrenoleukodystrophy 4, 6, 9. They are not proof that KPV improves symptoms, lowers inflammation, or changes disease course.
What outcomes have not been established
- KPV has not been shown in the supplied evidence to improve ulcerative colitis symptoms in patients.
- KPV has not been shown in the supplied evidence to heal wounds or repair the skin barrier in patients.
- KPV has not been shown in the supplied evidence to reduce pain, speed recovery, or improve immune health in patients.
- KPV safety, interactions, and long-term risks are not established from the supplied KPV-specific evidence.
One supplied ulcerative-colitis-related record studied a peptide receptor-targeted fluorescent probe for visualization and discrimination between chronic and acute ulcerative colitis 10. That is research-methodology evidence, not proof that KPV is a treatment for ulcerative colitis.
What studies exist
| Year | Design | Study | Journal | Record |
|---|---|---|---|---|
| 2022 | Randomised controlled trial | Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia | The New England journal of medicine | PMID 35320643 |
| 2022 | Randomised controlled trial | Trial of Erythropoietin for Hypoxic-Ischemic Encephalopathy in Newborns | The New England journal of medicine | PMID 35830641 |
| 2022 | Randomised controlled trial | Interobserver Variability in CT-based Morphologic Tumor Response Assessment of Colorectal Liver Metastases | Radiology. Imaging cancer | PMID 35522139 |
| 2021 | Clinical trial | Irreversible Electroporation to Treat Unresectable Colorectal Liver Metastases (COLDFIRE-2): A Phase II, Two-Center, Single-Arm Clinical Trial | Radiology | PMID 33724066 |
| 2025 | Randomised controlled trial | Clinical efficacy and safety of two highly purified human menopausal gonadotropins in women undergoing in vitro fertilization | Reproduction & fertility | PMID 40445794 |
| 2020 | Clinical trial | Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study | Radiology | PMID 31687922 |
| 2016 | Randomised controlled trial | Predictors of difficult videolaryngoscopy with GlideScope® or C-MAC® with D-blade: secondary analysis from a large comparative videolaryngoscopy trial | British journal of anaesthesia | PMID 27317711 |
| 1984 | Primary study | Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit | Peptides | PMID 6333677 |
| 2022 | Primary study | International Recommendations for the Diagnosis and Management of Patients With Adrenoleukodystrophy: A Consensus-Based Approach | Neurology | PMID 36175155 |
| 2017 | Review / secondary | Tubulointerstitial nephritis and uveitis | Current opinion in ophthalmology | PMID 28806188 |
| 2020 | Primary study | Correction: Stunting is not a synonym of malnutrition | European journal of clinical nutrition | PMID 31636408 |
| 2020 | Primary study | Stunting is not a synonym of malnutrition | European journal of clinical nutrition | PMID 31142828 |
This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-07.
Reported dosing ranges
No patient dosing recommendation for KPV can be made from the supplied KPV-specific evidence. The available records support a discussion of evidence gaps, route and formulation concerns, and the need for licensed clinician review—not a protocol.
| Source type | What was studied or labelled | Reported dose or range | What it can and cannot tell a patient |
|---|---|---|---|
| KPV-specific animal study | Alpha-MSH 11-13, named lysine-proline-valine, in rabbit fever research 8 | No patient dosing range can be taken from this brief | Animal fever research cannot be converted into human dosing advice. |
| KPV-specific cell study | Alpha-MSH, MSH 11-13 KPV, and ACTH signaling in human keratinocyte cells 12 | No human dosing range | Cell signaling research does not show what dose, route, or schedule would be safe or useful in people. |
| Indirect human randomized trial records | Human RCTs in unrelated or indirect clinical areas 1, 2, 3, 5, 7 | No KPV patient dosing range established | These records should not be used as KPV dosing support. |
| Human therapeutic KPV dosing | No supplied registered trials and no supplied KPV-specific human therapeutic dosing record | No human dosing has been published in the supplied evidence | A licensed clinician should review risks rather than relying on online protocols. |
Why route, formulation, purity, and clinical context matter
With peptides, route matters because oral, nasal, topical, and injectable forms can expose the body differently. Formulation, sterility, identity testing, impurities, and storage also matter, especially when a product comes from a non-prescription research-chemical source rather than a licensed pharmacy.
When to ask a licensed clinician instead of following online protocols
Ask a licensed clinician before considering any peptide if you are pregnant, breastfeeding, managing a serious illness, taking immune-active medications, or combining multiple drugs or supplements. If you are comparing internet dosing charts, our KPV peptide injection dosage article explains why online protocols often go beyond the evidence.
Legal status
| Date | Action | What it means | Source | Evidence |
|---|---|---|---|---|
| 2026-07-23 | Advisory committee reportedly voted 8-6-1 in favour of including KPV on the 503A bulk drug substances list | Advisory vote only, as reported. FDA has not added it to the list, and the substance is not FDA-approved. | Healio (2026-07-24) | Reported — no agency record |
| 2026-07-23 | FDA convened the Pharmacy Compounding Advisory Committee to consider seven peptide bulk drug substances for the 503A list | The meeting establishes that these substances were formally considered. It does not change any substance's status. | FDA Advisory Committee Calendar | FDA / Federal Register |
This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-07. See the full legal-status tracker for every compound we follow.
Safety
KPV safety is not established from the supplied KPV-specific evidence. Animal fever work and cell signaling work cannot define common side effects, rare risks, contraindications, or long-term safety in people 8, 12.
Why safety is not established from limited or preclinical evidence
A rabbit fever study can show what happened in that animal model, but it cannot tell us the rate of side effects in people 8. A human keratinocyte cell study can show signaling in cells, but it cannot show whether a person will have irritation, allergy, infection, immune effects, or drug interactions 12.
Possible risks from non-prescription or research-chemical products
Research-chemical products carry a different risk profile than clinician-prescribed medications from licensed pharmacies. The main concerns are identity, purity, sterility, dosing accuracy, storage, and whether the material was made for human use.
- Identity risk: the vial may not contain what the label says.
- Purity risk: impurities or byproducts may be present.
- Sterility risk: injectable material may be contaminated.
- Dose-accuracy risk: the amount in each vial or spray may not match the label.
- Oversight risk: there may be no clinician checking contraindications, side effects, or interactions.
For more detail on evaluating sources, see our patient guide to finding a legitimate peptide source. The key safety idea is not hype or fear; it is the difference between licensed care and unregulated supply.
Special caution for pregnancy, breastfeeding, serious illness, immune conditions, and multiple medications
People who are pregnant, trying to conceive, breastfeeding, immunocompromised, living with cancer, managing autoimmune disease, or taking several medications need extra caution. The supplied KPV-specific evidence does not establish safety for these groups 8, 12.
Interactions
No dedicated KPV interaction studies were supplied. That is not the same as saying there are no interactions; it means interaction risk has not been well defined in the evidence set provided.
Why interaction evidence is limited
The supplied KPV-specific records include animal fever research and human keratinocyte cell signaling research 8, 12. Those study types do not answer how KPV might interact with prescription drugs, supplements, immune therapies, dermatology treatments, or gastrointestinal medications.
Why immune-modulating, inflammatory, dermatologic, and gastrointestinal conditions require clinician review
KPV is discussed in inflammation-related contexts, but that does not make it safe to combine with immune-active drugs or to use in inflammatory disease without review. The supplied ulcerative-colitis-related record is about an imaging probe method, not a KPV treatment trial 10.
What information to share with a clinician before considering any peptide
- Your diagnoses, including autoimmune, inflammatory, skin, gut, liver, kidney, neurologic, or cancer history.
- All prescription medicines, over-the-counter medicines, supplements, and hormones.
- Pregnancy plans, pregnancy status, or breastfeeding status.
- Prior reactions to peptides, injections, topical products, preservatives, or adhesives.
- Why you are considering the peptide and what outcome you hope to track.
How to obtain it legally
The safer process for any peptide starts with a licensed clinician evaluation, not an anonymous checkout page. Chia does not currently offer KPV, so we do not route readers to a KPV product or imply it can be obtained through Chia.
Clinician evaluation before use
A clinician evaluation reviews your health history, medications, goals, allergies, prior reactions, and risk factors. It also gives you a place to ask whether the evidence actually matches your goal and whether a safer or better-studied option exists.
Prescription and pharmacy safeguards when a medication is clinically appropriate
When Chia offers a treatment, the process is 100% online: a short health questionnaire, review by a licensed US provider, and prescribing only when clinically appropriate. A prescription is never guaranteed. Chia-offered compounded medications are prepared by state-licensed US 503A pharmacies and shipped to the patient’s door; compounded drugs are not FDA-approved.
For example, Chia offers certain longevity and metabolic treatments such as GHK-Cu cream, NAD+ injection or nasal spray, glutathione injection or nasal spray, and sermorelin injection, nasal spray, or tablets. KPV is not one of the treatments in our current catalog.
What a research-chemical vendor is not
A research-chemical vendor is not a substitute for a licensed clinician, a prescription, or a state-licensed pharmacy. “Research use only” material is not made for patient use, and it may not come with the safeguards patients expect for identity, purity, sterility, or clinical oversight.
How Chia approaches peptides it does offer, and why KPV is education-only at Chia
At Chia, we write about peptides we do not offer because patients still need clear, non-hype education. If your real goal is inflammation, skin health, recovery, energy, sexual health, weight care, or healthy aging, a licensed provider can help sort evidence, risk, and options without turning a research peptide into a promise.
How does KPV compare with BPC-157 and other healing peptides?
KPV is usually discussed as an alpha-MSH-related anti-inflammatory signaling peptide, while BPC-157 is usually discussed in tissue-repair contexts. Neither comparison should be treated as treatment advice, and KPV-specific human benefits are not established from the supplied evidence 8, 12.
| Peptide | Common research framing | Evidence caution | Chia availability |
|---|---|---|---|
| KPV | Alpha-MSH 11-13; anti-inflammatory signaling discussion | KPV-specific supplied evidence includes animal and cell work; patient outcomes are not established 8, 12 | Not currently offered by Chia |
| BPC-157 | Tissue repair and healing research discussion | Should be evaluated separately; comparison claims are not dosing or treatment advice | Not currently offered by Chia |
| GHK-Cu | Copper peptide used in skin and tissue-remodeling discussions | Evidence and route depend on formulation and indication | Chia offers GHK-Cu cream from $159/mo |
| Glutathione | Antioxidant biology and oxidative-stress discussions | Goals, route, and safety should be reviewed by a clinician | Chia offers injection and nasal spray forms from $179/mo |
If you are comparing KPV with BPC-157, start with the evidence limits and side effects rather than social-media claims. Our guides to KPV side effects and KPV and BPC-157 side effects can help you frame better questions for a clinician.
FAQ
KPV is mainly discussed for anti-inflammatory signaling, but the supplied KPV-specific evidence does not establish a proven treatment benefit in people. It is better described as a research peptide with animal and cell evidence, not a proven therapy.
KPV is usually discussed as an alpha-MSH-related anti-inflammatory signaling peptide. BPC-157 is usually discussed in tissue-repair research. They have different proposed mechanisms, and neither comparison should be used as a dosing plan or treatment recommendation.
People who are pregnant, breastfeeding, trying to conceive, immunocompromised, living with serious illness, taking immune-active drugs, or using multiple medications should not consider KPV without clinician review. Safety is not established for these groups from the supplied evidence.
The supplied KPV-specific evidence does not establish whether tiredness is a common side effect. If fatigue occurs after using any peptide or supplement, stop relying on online advice and speak with a licensed clinician.
No. Chia does not currently offer KPV. Chia does offer certain other clinician-reviewed compounded treatments, but KPV is education-only at Chia.
KPV is discussed in gut-inflammation and skin-signaling contexts, but the supplied evidence does not prove that it improves gut inflammation or skin healing in patients. Cell, animal, imaging, or method studies should not be treated as patient outcome trials.
The assigned evidence grade is A, meaning two or more human randomized controlled trials are indexed. That grade describes the quantity and design of indexed evidence, not whether KPV works or is safe.
No standard patient dosing recommendation can be made from the supplied KPV-specific evidence. Online dosing protocols should not replace a licensed clinician’s review.
References
- 1.PMID 35320643 [randomised controlled trial] Watterberg KL, Walsh MC, Li L, et al. Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia. The New England journal of medicine. 2022.
- 2.PMID 35830641 [randomised controlled trial] Wu YW, Comstock BA, Gonzalez FF, et al. Trial of Erythropoietin for Hypoxic-Ischemic Encephalopathy in Newborns. The New England journal of medicine. 2022.
- 3.PMID 35522139 [randomised controlled trial] Wesdorp NJ, Kemna R, Bolhuis K, et al. Interobserver Variability in CT-based Morphologic Tumor Response Assessment of Colorectal Liver Metastases. Radiology. Imaging cancer. 2022.
- 4.PMID 33724066 [clinical trial] Meijerink MR, Ruarus AH, Vroomen LGPH, et al. Irreversible Electroporation to Treat Unresectable Colorectal Liver Metastases (COLDFIRE-2): A Phase II, Two-Center, Single-Arm Clinical Trial. Radiology. 2021.
- 5.PMID 40445794 [randomised controlled trial] Rao KA, Khanna G, Bavishi H, et al. Clinical efficacy and safety of two highly purified human menopausal gonadotropins in women undergoing in vitro fertilization. Reproduction & fertility. 2025.
- 6.PMID 31687922 [clinical trial] Ruarus AH, Vroomen LGPH, Geboers B, et al. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study. Radiology. 2020.
- 7.PMID 27317711 [randomised controlled trial] Aziz MF, Bayman EO, Van Tienderen MM, et al. Predictors of difficult videolaryngoscopy with GlideScope® or C-MAC® with D-blade: secondary analysis from a large comparative videolaryngoscopy trial. British journal of anaesthesia. 2016.
- 8.PMID 6333677 [primary study] Richards DB, Lipton JM. Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit. Peptides. 1984.
- 9.PMID 36175155 [primary study] Engelen M, van Ballegoij WJC, Mallack EJ, et al. International Recommendations for the Diagnosis and Management of Patients With Adrenoleukodystrophy: A Consensus-Based Approach. Neurology. 2022.
- 10.PMID 28349696 [primary study] Zeng M, Shao A, Li H, et al. Peptide Receptor-Targeted Fluorescent Probe: Visualization and Discrimination between Chronic and Acute Ulcerative Colitis. ACS applied materials & interfaces. 2017.
- 11.PMID 36240893 [primary study] Zhao Y, Huang L, Lin G, et al. Skin-adaptive film dressing with smart-release of growth factors accelerated diabetic wound healing. International journal of biological macromolecules. 2022.
- 12.PMID 15102092 [primary study] Elliott RJ, Szabo M, Wagner MJ, et al. alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. The Journal of investigative dermatology. 2004.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if peptide therapy is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
